These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 11249685)
1. The next generation of vaccines for the treatment of cancer. Long L; Glover RT; Kaufman HL Curr Opin Mol Ther; 1999 Feb; 1(1):57-63. PubMed ID: 11249685 [No Abstract] [Full Text] [Related]
2. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
3. Clinical development of MVA-based therapeutic cancer vaccines. Acres B; Bonnefoy JY Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940 [TBL] [Abstract][Full Text] [Related]
5. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065 [TBL] [Abstract][Full Text] [Related]
6. Costimulatory molecules in vaccine design. Hodge JW; Schlom J Ernst Schering Res Found Workshop; 2000; (30):23-52. PubMed ID: 10943315 [No Abstract] [Full Text] [Related]
7. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. Marshall JL; Gulley JL; Arlen PM; Beetham PK; Tsang KY; Slack R; Hodge JW; Doren S; Grosenbach DW; Hwang J; Fox E; Odogwu L; Park S; Panicali D; Schlom J J Clin Oncol; 2005 Feb; 23(4):720-31. PubMed ID: 15613691 [TBL] [Abstract][Full Text] [Related]
9. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Aarts WM; Schlom J; Hodge JW Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537 [TBL] [Abstract][Full Text] [Related]
10. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Greiner JW; Zeytin H; Anver MR; Schlom J Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911 [TBL] [Abstract][Full Text] [Related]
11. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related]
12. Carcinoembryonic antigen as a target for cancer vaccines. Hodge JW Cancer Immunol Immunother; 1996 Nov; 43(3):127-34. PubMed ID: 9001565 [TBL] [Abstract][Full Text] [Related]
13. Vaccines: an innovative approach to treating cancer. Pazdur MP; Jones JL J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219 [TBL] [Abstract][Full Text] [Related]
14. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Seremet T; Brasseur F; Coulie PG Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282 [TBL] [Abstract][Full Text] [Related]